Ben R. Taylor, Chief Financial Officer of RECURSION PHARMACEUTICALS, INC. (NASDAQ:RXRX), sold 21,383 shares of Class A Common Stock at a price of $4.18 on December 29, 2025, according to a Form 4 ...
CEO Chris Gibson highlighted significant progress in 2024, including clinical data readouts from REC-617 and REC-994, which showed early efficacy signals and robust safety, respectively. REC-617, a ...
Condé Nast Traveler readers believe this major US city is the end-all-be-all for shopping destinations in the country.